From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...
Lily Allen foi vista em um estúdio de gravação nesta quinta-feira (6), compartilhando com seus seguidores imagens ao lado da ...
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback